CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on
Wednesday, January 18
10:00 AM ET
January 5, 2023
CNS Pharmaceuticals, Inc.
(NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that
, Chief Executive Officer
of CNS Pharmaceuticals will present at the
Virtual Investor 2023 Companies to Watch Event
Wednesday, January 18, 2023
10:00 AM ET
live video webcast
of the presentation will be available on the
page of the
section of the Company’s website (
). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
View original content to download multimedia:
SOURCE CNS Pharmaceuticals, Inc.